EUVIMEDEUVIMED entdecken
Crossref

Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent

Yu Huang, Waisi Eng, Chong Shao, Gaoliang Cheng, Changwu Qiang, Wei Peng, Si Yang iD, Shiguo Liu

Journal of Labelled Compounds and Radiopharmaceuticals · 2025

DOI: 10.1002/jlcr.4142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von Yu Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hubei NO.3 People's Hospital of Jianghan University, Wuhan, China. Hauptthemen laut MEDLINE: Carbonic Anhydrase IX, Carcinoma, Renal Cell, Kidney Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The protein carbonic anhydrase IX (CAIX) is highly expressed in clear cell renal cell carcinoma (ccRCC), and its restrictive expression in healthy tissues makes CAIX an attractive diagnostic target. The purpose of this study was to synthesize and evaluate [ 18 F]AlF‐NY104, a small‐molecule CAIX‐targeting PET agent in a preclinical ccRCC model. The radiolabeling parameters for [ 18 F]AlF‐NY104 have been optimized, including the solvent volume and reaction temperature. The high‐purity product was synthesized by using an automated multifunctional module Mortenon M1, leading to nondecay‐corrected radiochemical yields over 50% ( n = 3). [ 18 F]AlF‐NY104 showed excellent tumor targeting capability and afforded high‐quality microPET/CT imaging in the OS‐RC‐2 tumor model (15.01 ± 0.76 %ID/g [mean ± SEM]). The radiation exposure from [ 18 F]AlF‐NY104 is estimated to be 4.44 mSv for adult male and female human subjects, which is well below the FDA recommended whole‐body single exposure limit of 30 mSv. Our investigation revealed that [ 18 F]AlF‐NY104 can be conveniently and efficiently radiolabeled by using an automated module. [ 18 F]AlF‐NY104 exhibited many outstanding properties, such as rapid uptake in tumor, rapid clearance through the kidney, and low uptake in most normal organs. Moreover, the high accumulation of [ 18 F]AlF‐NY104 in tumors in CAIX‐positive models offers an alternative diagnostic strategy for patients with ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic Anhydrase IXCarcinoma, Renal CellKidney NeoplasmsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAntigens, NeoplasmBiomarkers, TumorCell Line, TumorXenograft Model Antitumor AssaysX-Ray MicrotomographyFluorine RadioisotopesRenal EliminationTissue DistributionHumansMaleFemaleAdultAnimalsMiceInjections, IntravenousRatsMice, Inbred BALB CRats, Sprague-DawleyMice, Nude

Stichwörter der Autor:innen

[18F]AlF‐NY104carbonic anhydrase IXclear cell renal cell carcinomaradiolabeling

Substanzen

CA9 protein, humanCarbonic Anhydrase IXAntigens, NeoplasmBiomarkers, TumorFluorine RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Hubei NO.3 People's Hospital of Jianghan University, Wuhan, China.
  • Norroy Bioscience Co., LTD, Wuxi, China.

ORCID-Profile: Si Yang

Zitieren

APA

Huang, Y., Eng, W., Shao, C., Cheng, G., Qiang, C., Peng, W., Yang, S., & Liu, S. (2025). Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4142

Vancouver

Huang Y, Eng W, Shao C, Cheng G, Qiang C, Peng W, et al. Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent. Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4142

BibTeX
@article{Huang2025,
  author = {Huang, Yu and Eng, Waisi and Shao, Chong and Cheng, Gaoliang and Qiang, Changwu and Peng, Wei and Yang, Si and Liu, Shiguo},
  title = {Synthesis, Preclinical Characterizations and Imaging Studies of [ 18 F]AlF‐Labeled NY104, a CAIX‐Targeting Diagnostic Agent},
  journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
  year = {2025},
  doi = {10.1002/jlcr.4142}
}
Kostenlos starten →